Towards Healthcare
Gastrointestinal Drugs Market Expands USD 55.85 Bn by 2034

Gastrointestinal Drugs Market Opportunities and Top Key Players

Based on market forecasts, the global gastrointestinal drugs market, projected at USD 40.21 billion in 2024, is expected to reach USD 55.85 billion by 2034, growing at a CAGR of 3.34% over the forecast period. The gastrointestinal drugs market is growing due to these drugs are used for various treatments in people with excess stomach acid, stomach or intestinal ulcers, or heartburn.

Content

  • Insight Code: 5766
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: June 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

About The Author

Kesiya Chacko is an accomplished market research professional with over 4+ years of experience in the healthcare industry, known for delivering actionable insights and strategic analysis that empower healthcare organizations to navigate complex, rapidly evolving markets.

Kesiya began her research career with Precedence Research, where she built a strong foundation in pharmaceutical and healthcare market analysis. Today, she plays an integral role at Towards Healthcare, contributing to in-depth, client-centric research initiatives. She also brings her expertise to Statifacts, supporting broader research functions with a focus on cross-sector healthcare trends and data interpretation.

Her commitment to high-quality analysis, combined with a strong grasp of regulatory and market dynamics, makes her a trusted contributor to healthcare firms seeking future-ready, data-backed decisions. Kesiya’s work spans the analysis of industry trends, competitive benchmarking, and evaluation of regulatory and innovation-driven shifts.

Talk to us
FAQ's

The gastrointestinal drugs market is projected to reach USD 55.85 billion by 2034, up from USD 41.55 billion in 2025, at a CAGR of 3.34%

Asia Pacific is the fastest-growing region due to rising healthcare infrastructure, increasing disposable income, and higher disease prevalence

Biologics and biosimilars are redefining treatment protocols by offering targeted therapy for chronic conditions like Crohn and UC

AI is transforming drug discovery, diagnostics, and patient stratification in gastroenterology.

Stringent FDA and EMA regulations ensure drug safety and efficacy but can delay product launches.

Drug formulation challenges such as low solubility, poor permeability, and mucosal barriers limit the bioavailability of some GI drugs

Major players include AbbVie, Pfizer, AstraZeneca, Takeda, Gilead Sciences, Biogen, and Janssen.
Any Questions